Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-3512676+ Erlotinib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Standard of Care chemotherapy plus experimental intervention (PF-3512676) |
| B | ACTIVE_COMPARATOR | Standard of Care chemotherapy |
| Name | Type | Description |
|---|---|---|
| PF-3512676 + Erlotinib | DRUG | PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity. Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity |
| Erlotinib | DRUG | Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity |
Inclusion Criteria: * Advanced, EGFR-positive NSCLC * ECOG Performance Status 0, 1 or 2 * Measurable disease Exclusion Criteria: * Known CNS metastasis * Pre-existing autoimmune or antibody mediated disease
PF-3512676 is an investigational small molecule being studied in oncology indications including non-small-cell lung carcinoma, melanoma, and cutaneous T-cell lymphoma. It has been evaluated in clinical trials for these conditions, though it remains in clinical development and is not approved.
PF-3512676 is a small molecule, but its specific molecular target has not been disclosed in available information. It is being studied for its potential effects in certain cancers, including non-small-cell lung carcinoma, melanoma, and cutaneous T-cell lymphoma.
PF-3512676 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 1 clinical development for oncology indications.
PF-3512676 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Clinical trials have been completed, but the drug is not yet available for commercial use.
PF-3512676 has been studied in several completed clinical trials, including NCT00043368, NCT00043420, and NCT00321815. These trials evaluated the drug in patients with melanoma, breast neoplasms, renal cell carcinoma, cutaneous T-cell lymphoma, and non-small-cell lung carcinoma.
Yes, PF-3512676 is also known as CPG 7909. Clinical trials have used both names to refer to the same investigational drug, which is being studied for its potential use in treating certain types of cancer.